Patent ID: 8784795

Claim:
A method for determining the efficacy of a candidate anti-prostate cancer therapy for a patient diagnosed with prostate cancer wherein the candidate anti-prostate cancer therapy comprises an immune cell activating agent and an antigen display enhancing agent that is able to stimulate or enhance the presentation of a cancer-specific antigen on the surface of prostate cancer cells, the method comprising: (a) incubating immune cells obtained from the patient with the immune cell activating agent to provide activated immune cells; (b) incubating prostate cancer cells from an established prostate cancer cell line with the antigen display enhancing agent, thereby providing treated prostate cancer cells; (c) contacting the activated immune cells with the treated prostate cancer cells; and (d) determining the ability of the activated immune cells to kill the treated prostate cancer cells, wherein the ability of the activated immune cells to kill the treated prostate cancer cells is indicative of the efficacy of the candidate anti-prostate cancer therapy.